The roles of non-coding RNAs in cardiac regenerative medicine

Choong, Oi Kuan; Lee, Desy S.; Chen, Chen-Yun; Hsieh, Patrick C.

doi:10.1016/j.ncrna.2017.06.001

Cited by 18 publications

(13 citation statements)

References 142 publications

(219 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among small ncRNAs, miRNAs are the most widely characterized [ 16 ]. MiRNAs are single-stranded ncRNAs of 19–24 nucleotides long, mainly known to be negative regulators of gene expression at the post-transcriptional level [ 17 , 18 ].…”

Section: Types Of Ncrnas and Molecular Functionmentioning

confidence: 99%

The noncoding-RNA landscape in cardiovascular health and disease

Mauro

Barandalla-Sobrados

Catalucci

2018

Non-coding RNA Research

View full text Add to dashboard Cite

The cardiovascular system plays a pivotal role in regulating and maintaining homeostasis in the human body. Therefore any alteration in regulatory networks that orchestrate heart development as well as adaptation to physiological and environmental stress might result in pathological conditions, which represent the leading cause of death worldwide [1]. The latest advances in genome-wide techniques challenged the “protein-central dogma” with the discovery of the so-called non-coding RNAs (ncRNAs). Despite their lack of protein coding potential, ncRNAs have been largely demonstrated to regulate the majority of biological processes and have also been largely implicated in cardiovascular disorders. This review will first discuss the important mechanistic aspects of some of the classes of ncRNAs such as biogenesis, mechanism of action, as well as their involvement in cardiac diseases. The ncRNA potential uses as therapeutic molecules, with a specific focus on the latest technologies for their in vivo delivery as drug targets, will be described.

show abstract

Section: Types Of Ncrnas and Molecular Functionmentioning

confidence: 99%

The noncoding-RNA landscape in cardiovascular health and disease

Mauro

Barandalla-Sobrados

Catalucci

2018

Non-coding RNA Research

View full text Add to dashboard Cite

show abstract

“…For example, combinations of microRNAs (miRNAs) and short‐interfering RNAs (siRNAs), each with different proapoptotic/antitumorigenic targets, were associated with greater tumor regression compared to treatment with individual ncRNAs . Similar therapeutic techniques have been applied to cardiovascular disease, where varying types of miRNAs are used together to target different proapoptotic markers and prevent myocardial cell death and promote angiogenesis . It may be possible, therefore, to use a combinatorial approach involving various types of ncRNAs to target pathological markers of ischemic stroke or to augment stroke therapy in the future.…”

Section: Overview Of Ncrnasmentioning

confidence: 99%

Noncoding RNAs in ischemic stroke: time to translate

Kaur

Sarmah

Saraf

et al. 2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Stroke is devastating and a major cause of morbidity and mortality around globe. Current interventions for ischemic stroke include thrombolytics, clot retrieval devices and/or intravenous tissue plasminogen activators (tPA), the latter two becoming the first line of treatment. Owing to the limitations of tPA to elicit therapeutic benefits in a narrow time window, new pharmacological interventions are needed. Exploring noncoding RNAs (ncRNAs) may be a promising option for stroke treatment. ncRNAs are endogenous molecules that play key roles in the pathophysiology of many functions and diseases, including during ischemic stroke. Small ncRNAs such as microRNAs, Piwi-interacting RNAs, and long ncRNAs affect the genetic machinery at molecular levels. These small ncRNAs, along with their target genes and RNA transcripts, are involved in repair and recovery mechanisms after stroke. The potential of ncRNAs to regulate physiological processes highlights their potential therapeutic importance. Here, we enumerate the details and roles of different types of ncRNAs as biomarkers and targets for future stroke intervention.

show abstract

“…Unfortunately, studies evaluating the true sensitivity and specificity of these ncRNAs as biomarkers in different populations are still lacking. Additionally, mimicking opioid cardioprotection through in vitro delivery of ncRNA as drug targets represents a promising therapeutic strategy for a myriad of cardiac conditions [ 174 ]. However, there is still not enough evidence on the effectiveness of these new approaches in CVD treatment and many challenges remain such as specific delivery, poor cellular uptake, off-target effects, and immunogenicity [ 175 ].…”

Section: Future Perspectivesmentioning

confidence: 99%

Novel Roles of Non-Coding RNAs in Opioid Signaling and Cardioprotection

Melo

Ishida

Goldaraz

et al. 2018

ncRNA

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a significant cause of morbidity and mortality across the world. A large proportion of CVD deaths are secondary to coronary artery disease (CAD) and myocardial infarction (MI). Even though prevention is the best strategy to reduce risk factors associated with MI, the use of cardioprotective interventions aimed at improving patient outcomes is of great interest. Opioid conditioning has been shown to be effective in reducing myocardial ischemia-reperfusion injury (IRI) and cardiomyocyte death. However, the molecular mechanisms behind these effects are under investigation and could provide the basis for the development of novel therapeutic approaches in the treatment of CVD. Non-coding RNAs (ncRNAs), which are functional RNA molecules that do not translate into proteins, are critical modulators of cardiac gene expression during heart development and disease. Moreover, ncRNAs such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are known to be induced by opioid receptor activation and regulate opioid signaling pathways. Recent advances in experimental and computational tools have accelerated the discovery and functional characterization of ncRNAs. In this study, we review the current understanding of the role of ncRNAs in opioid signaling and opioid-induced cardioprotection.

show abstract

The roles of non-coding RNAs in cardiac regenerative medicine

Cited by 18 publications

References 142 publications

The noncoding-RNA landscape in cardiovascular health and disease

The noncoding-RNA landscape in cardiovascular health and disease

Noncoding RNAs in ischemic stroke: time to translate

Novel Roles of Non-Coding RNAs in Opioid Signaling and Cardioprotection

Contact Info

Product

Resources

About